Necmi Eren

1.9k total citations · 2 hit papers
31 papers, 547 citations indexed

About

Necmi Eren is a scholar working on Nephrology, Hematology and Surgery. According to data from OpenAlex, Necmi Eren has authored 31 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Nephrology, 10 papers in Hematology and 5 papers in Surgery. Recurrent topics in Necmi Eren's work include Renal Diseases and Glomerulopathies (8 papers), Platelet Disorders and Treatments (5 papers) and Chronic Kidney Disease and Diabetes (4 papers). Necmi Eren is often cited by papers focused on Renal Diseases and Glomerulopathies (8 papers), Platelet Disorders and Treatments (5 papers) and Chronic Kidney Disease and Diabetes (4 papers). Necmi Eren collaborates with scholars based in Türkiye, United States and Czechia. Necmi Eren's co-authors include Martin J. Vincent, Mehmet Sönmez, Rahmet Çaylan, Vladimı́r Tesař, Volkan Korten, Stuart T. Nichol, Richard Lafayette, Jonathan Barratt, İftihar Köksal and Thomas G. Ksiazek and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Necmi Eren

25 papers receiving 514 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

2023 121 citations Richard Lafayette, Jens Kristensen et al. The Lancet profile →
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

2024 51 citations Richard Lafayette, Sean Barbour et al. Kidney International profile →

Peers

Countries citing papers authored by Necmi Eren

Since Specialization

Citations

This map shows the geographic impact of Necmi Eren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Necmi Eren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Necmi Eren more than expected).

Fields of papers citing papers by Necmi Eren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Necmi Eren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Necmi Eren. The network helps show where Necmi Eren may publish in the future.

Co-authorship network of co-authors of Necmi Eren

This figure shows the co-authorship network connecting the top 25 collaborators of Necmi Eren. A scholar is included among the top collaborators of Necmi Eren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Necmi Eren. Necmi Eren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	#2859 ORIGIN 2b: changes in Gd-IgA1 and eGFR after discontinuation of atacicept treatment in IgA nephropathy 2025 ·Nephrology Dialysis Transplantation ·Jonathan Barratt, Sean Barbour, Robert Brenner, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimı́r Tesař, Richard Lafayette	0
2	Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2022 Turkish Society of Nephrology Registry Report 2024 ·SHILAP Revista de lepidopterología ·Nurhan Seyahi, İsmail Koçyiğit, Necmi Eren, Halil Zeki Tonbul, Erhan Tatar, Zülfükar Yılmaz, Ebru Gök Oğuz, Ercan Türkmen, Kenan Ateş	2
3	A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy breakdown → 2024 ·Kidney International ·Richard Lafayette, Sean Barbour, Rubeen Israni, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimı́r Tesař, Celia J. F. Lin, Jonathan Barratt	51
4	Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy 2024 ·Journal of the American Society of Nephrology ·Jonathan Barratt, Sean J. Barbour, Robert Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimı́r Tesař, Richard Lafayette, (unknown)	15
5	Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN) 2024 ·Journal of the American Society of Nephrology ·Jonathan Barratt, Sean Barbour, Robert Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimı́r Tesař, (unknown)	1
6	WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL 2024 ·Kidney International Reports ·Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimı́r Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette	0
7	Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial breakdown → 2023 ·The Lancet ·Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimı́r Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt	121
8	Therapetic Plasmapheresis: A Retrospective Study; 12 Years of Single Center Experience 2022 ·Kocaeli Medical Journal ·(unknown), Sibel Gökçay Bek, (unknown), Necmi Eren, Erkan Dervişoğlu, Betül Kalender	0
9	Impact of COVID‐19 lockdown on mood status: A comparison of hemodialysis and oncology patients 2021 ·Therapeutic Apheresis and Dialysis ·Selma Alagöz, Necmi Eren, (unknown), (unknown), Özlem Özkul, Hasan Belli, Numan Görgülü, (unknown), Nurhan Seyahi	2
10	How Dialysis Patients Cope with a Curfew? A Comparison of Psychological Status between Hemodialysis and Peritoneal Dialysis Patients During the COVID-19 Pandemic 2021 ·Blood Purification ·(unknown), Necmi Eren, (unknown), Şenol Turan, (unknown), (unknown), (unknown), Sibel Gökçay Bek, Alev Bakır, Erkan Dervişoğlu, Nurhan Seyahi, Sinan Trabulus	5
11	Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients 2021 ·Indian Journal of Hematology and Blood Transfusion ·(unknown), Özgür Mehtap, (unknown), Pınar Tarkun, (unknown), Necmi Eren, Abdullah Hacıhanefioğlu	0
12	Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor? 2020 ·PLoS ONE ·Selma Alagöz, (unknown), Necmi Eren, Alev Bakır, (unknown), Sinan Trabulus, Nurhan Seyahi	15
13	Renal Tubular Acidosis in Patients with Systemic Lupus Erythematosus 2020 ·Kidney & Blood Pressure Research ·Necmi Eren, Özkan Güngör, (unknown), (unknown), (unknown), Gözde Yıldırım Çetin, Ayten Yazıcı, Sibel Gökçay Bek, (unknown), Orçun Altunören, Ayşe Çefle	5
14	Usefulness of Peritoneal Ultrafiltration in Patients with Diuretic Resistant Heart Failure without End-Stage Renal Disease 2020 ·Cardiorenal Medicine ·(unknown), Sibel Gökçay Bek, Necmi Eren, (unknown), (unknown), (unknown), Tayfun Şahı̇n, Erkan Dervişoğlu, Betül Kalender	2
15	Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura 2018 ·Transfusion and Apheresis Science ·(unknown), Özgür Mehtap, (unknown), Pınar Tarkun, Necmi Eren, (unknown), Abdullah Hacıhanefioğlu	10
16	Rh (D) alloimmunization treated by double filtration plasmapheresis 2018 ·Transfusion and Apheresis Science ·Sibel Gökçay Bek, Necmi Eren, Ant Uzay, (unknown)	4
17	The relation between hemoglobin variability and carotid intima-media thickness in chronic hemodialysis patients 2017 ·International Urology and Nephrology ·(unknown), Orçun Altunören, Ertuğrul Erken, Ismet Onder Isık, (unknown), Necmi Eren, (unknown), Özkan Güngör	5
18	Is Nebivolol Really Effective in Preventing Contrast Induced Nephropathy? 2015 ·Kidney & Blood Pressure Research ·Orçun Altunören, Mehmet Ballı, Necmi Eren, Hakan Taşolar, (unknown), (unknown), (unknown), Özkan Güngör	8
19	Epicardial Adipose Tissue Thickness in Hemodialysis Patients 2013 ·Journal of the American College of Cardiology ·Burak Altun, Hakan Taşolar, Necmi Eren, (unknown), (unknown), Ahmet Temız, Emıne Gazı, Ahmet Barutçu, Orçun Altunören, Yücel Çölkesen	3
20	Epicardial Adipose Tissue Thickness in Hemodialysis Patients 2013 ·Echocardiography ·Burak Altun, Hakan Taşolar, Necmi Eren, (unknown), (unknown), Ahmet Temız, Emıne Gazı, Ahmet Barutçu, Orçun Altunören, Yücel Çölkesen, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact